A single-center phase 2 trial with a meaningful primary endpoint (40% complete response) and acceptable safety, but limited by lack of control group, modest sample size, and single-center design requiring confirmation in larger studies.
This is a mechanistic study using in vitro biochemistry and cell/animal models to propose a novel pathway; it raises a question about fructose's direct effects on mitochondria rather than providing clinical evidence ready to guide practice.
Phase II RCT with clear dose-dependent weight loss versus placebo and metabolic benefits, but limited to 16 weeks and requiring Phase III confirmation before clinical adoption.
A comprehensive review article synthesizing current concepts, mechanisms, and translational principles for cancer stem cell targeting, offering expert guidance on scientific and clinical approaches rather than reporting original trial data.
A multicenter retrospective real-world study with propensity weighting showing clinically meaningful improvements in response rates, PFS, and OS for a novel embolic agent versus standard care, but limited by retrospective design and real-world (non-randomized) conduct.
Mechanistic in vitro study demonstrating a novel biological principle (HIF-2α-driven E1A upregulation under hypoxia) without clinical outcomes, efficacy data, or in vivo therapeutic validation.
This is a narrative review synthesizing preclinical logic and early clinical experience across diverse non-oncologic diseases, but reports no original trial data, effect sizes, or comparative outcomes to support practice change.